Mirum Pharmaceuticals (MIRM) Change in Accured Expenses (2019 - 2026)

Mirum Pharmaceuticals' Change in Accured Expenses history runs 8 years deep, the most recent figure standing at $57.2 million for Q1 2026.

• In Q1 2026, Change in Accured Expenses rose 387.72% year-over-year to $57.2 million; the TTM figure through Mar 2026 stood at $95.6 million (up 134.5% YoY), while the FY2025 annual figure was $50.1 million, up 24.29% from the prior year.
• Change in Accured Expenses for Q1 2026 stood at $57.2 million, up from $3.4 million in the prior quarter.
• The five-year high for Change in Accured Expenses was $57.2 million in Q1 2026, with the low at -$8.1 million in Q1 2022.
• The 5-year median for Change in Accured Expenses is $9.3 million (2024), against an average of $10.9 million.
• The sharpest annual moves came in 2022 and 2023: Change in Accured Expenses plunged 146.84% in 2022, then jumped 250660.0% in 2023.
• Mirum Pharmaceuticals' Change in Accured Expenses stood at -$5000.0 in 2022, then surged by 250660.0% to $12.5 million in 2023, then fell by 25.45% to $9.3 million in 2024, then plunged by 63.13% to $3.4 million in 2025, then surged by 1562.62% to $57.2 million in 2026.
• Business Quant data shows MIRM's Change in Accured Expenses at $57.2 million in Q1 2026, $3.4 million in Q4 2025, and $24.3 million in Q3 2025.